Brief report of Anti-PD1 in HIV setting: relevant and breaking results in first-line Non Small Cell Lung Cancer therapy

Lise Bertin, Anthony Canellas, Baptiste Abbar, Marianne Veyri, Jean-Philippe Spano, Jacques Cadranel, Armelle Lavolé

To cite this version:

HAL Id: hal-03412658
https://hal.sorbonne-universite.fr/hal-03412658
Submitted on 3 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Brief report of Anti-PD1 in HIV setting: relevant and breaking results in first-line Non Small Cell Lung Cancer therapy

Lise Bertin, Anthony Canellas, Baptiste Abbar, Marianne Veyri, Jean-Philippe Spano, Jacques Cadranel, Armelle Lavolé

PII: S2666-3643(21)00106-5
DOI: https://doi.org/10.1016/j.jtocrr.2021.100247
Reference: JTOCRR 100247

To appear in: JTO Clinical and Research Reports

Received Date: 21 July 2021
Revised Date: 14 October 2021
Accepted Date: 17 October 2021


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.
Brief report of Anti-PD1 in HIV setting: relevant and breaking results in first-line Non Small Cell Lung Cancer therapy

Lise Bertin¹, Anthony Canellas¹,², Baptiste Abbar³,⁴,⁵, Marianne Veyri³,⁴,⁵, Jean-Philippe Spano³,⁴,⁵, Jacques Cadranel¹,² Armelle Lavolé¹,²

¹ Service de Pneumologie et Oncologie thoracique, Assistance Publique-Hôpitaux de Paris (APHP). Sorbonne Université, Hôpital Tenon, Paris, France
² GRC 04 Theranoscan, Sorbonne Université, Paris, France
³ Pitié Salpêtrière Hospital, Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France
⁴ Institut Pierre Louis d’Épidémiologie et de Santé Publique (iPLESP), INSERM, Sorbonne Université, Paris, France
⁵ Institut Universitaire de Cancérologie, CLIP² Galilée, Paris, France

*Corresponding author*: A. Lavolé, MD, Service de Pneumologie et Oncologie thoracique Assistance Publique-Hôpitaux de Paris (AP-HP), Hopital Tenon, Paris, France. Email: armelle.lavole@aphp.fr.

Abstract

In the recent past, we observed an increased risk of cancer in the HIV population due to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clinical trials, and up-to-date recommendations for these patients are lacking. Only few cases of HIV patients suffering from cancer and undergoing first-line immunotherapy have been reported so far. Here we report the largest known study of HIV patients with non-small cell lung cancer (NSCLC) (5 patients) undergoing first-line immunotherapy by pembrolizumab, following CANCERVIH group selection. Our results are consistent with previous case reports concerning safety of immunotherapy in HIV patients, showing no severe or fatal toxicity, opportunistic infections, or immune reconstitution inflammatory syndrome (IRIS). Moreover, pembrolizumab did not seem to modify HIV viral parameters. We also assessed effectiveness of immunotherapy in these HIV-immunosuppressed patients: the average survival was 9.8 months, with three patients showing rapid progression and two partial response. However, as well as safety and drug-to-drug interactions, the effectiveness of first-line immunotherapy in people living with HIV (PLWHIV) needs to be supported by larger studies.

Manuscript word count: 1300 words (without abstract)

Key words: HIV, anti-PD-1, CD4⁺, viral load, lung cancer.
**Conflict of interest:**
Jacques Cadranel received fees from Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Merck Sharp Dohme, Pfizer, Roche and Takeda for participation to boards of experts.
Jean-Philippe Spano declares links of interest with Roche, MSD, Astra Zeneca, Leopharma, Mylan, Biogaran, Novartis, Daiichi Sankyo Oncology, Pfizer, Bristol Myers Squibb, Incyte, Pierre Fabre Oncology, Lilly, Gilead.
Armelle Lavolé reports non-financial support from Bristol Myers Squibb.
Anthony Canellas received fees from Bristol Myers Squibb.
The others authors declare no conflicts of interests.

**Introduction**

The use of highly active antiretroviral therapy (HAART) in developed countries has led to considerable reduction in AIDS mortality caused by opportunistic infections and AIDS-defining cancers. Instead, non-AIDS-related cancers have become a leading cause of morbidity and mortality in people living with HIV (PLWHIV), with non-small cell lung cancer (NSCLC) being the first cause of mortality [1]. Because of a possible drug-to-drug interaction between chemotherapy and HAART, these patients require particular monitoring.

In the last 5 years, immune checkpoint inhibitors (ICIs) – notably programmed cell death 1 (PD-1)/programmed cell death 1 ligand (PD-L1) inhibitors – have become the standard-of-care for advanced NSCLC in the general population, initially as second-line [2], then as first-line treatment in patients with \( \geq 50\% \) tumour PD-L1 expression [3], and finally in combination with chemotherapy in all patients, except those with oncogene-driven NSCLC. Since ICIs act by suppressing immune tolerance and by reactivating an effective immune response, major concerns in PLWHIV were: i) a lack of anti-tumoral response due to HIV-related chronic immune deficiency, and ii) the risk of anti-HIV response modulation and deregulation of immune parameters, potentially leading to immune reconstitution inflammatory syndrome (IRIS).

Until recently, this population was rarely studied: only few cases in phase I and II clinical trials had described the use of ICIs as second or subsequent lines of treatment for PLWHIV with advanced NSCLC [4]. The CHIVA 2 trial has recently addressed the possible use of immunotherapy as second-line treatment of PLWHIV with advanced NSLCL [5]; however, safety and efficacy data on ICIs as first-line therapy are still lacking.
The French CANCERVIH network is a multidisciplinary task force supported by the French National Cancer Institute (INCa) whose mission is to optimise management and care of PLWHIV and suffering from cancer. A main objective of CANCERVIH is to ensure equal care for PLWHIV, particularly through access to therapeutic innovations including immunotherapy [6]. Here, we report 5 cases taken from the CANCERVIH database of PLWHIV with advanced NSCLC and treated with first-line pembrolizumab

**Methods**

The CANCERVIH working group [7] has recommended that all new cases of PLWHIV with cancer should be included in the CANCERVIH database and discussed during the bi-monthly national multidisciplinary board. Moreover, recommendations for immuno-virological monitoring have been published [8].

Between January 2014 and December 2019, 105 PLWHIV suffering from lung cancer at various stages were presented. Among them, five with advanced NSCLC were eligible for first-line pembrolizumab monotherapy, having an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1; PD-L1 tumour expression ≥50%, and patient agreement.

All patients received a fixed dose of 200 mg pembrolizumab every 3 weeks until disease progression or unacceptable toxicity. The outcome of this treatment is reported here (Table 1). The data for this analysis were collected from CANCERVIH database which one has received an approval from the French IRB (n°15-009), the CCTIR (n°16-391) and from the “Commission Nationale de l’Informatique et des Libertés (CNIL n°916500)” and as a retrospective analysis no consent is required.

**Results**

The median age was 57.4 years (range 50-69) and 4 patients were men. Apart from 1 patient (Case 3), all were current or former smokers. The prevalent histology was squamous and undifferentiated carcinoma; only 1 patient had adenocarcinoma. Tumour cell PD-L1 expression was 80% in 2 cases (Cases 1 and 3). No epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) aberrations were found. All patients had undetectable plasma HIV load and were stable under antiretroviral treatment, except Case 4, who had concomitant advanced NSCLC and HIV diagnostics (HIV load: 44 500 copies/mL). Median CD4+ lymphocyte count was 595/mm³ (range 76-1024). No opportunistic infection was reported.
At the cut-off date of data analysis (March 2020), median overall survival was 9.8 months (range 1-25) and patients received a median of 9 pembrolizumab infusions (range 1-28) (Table 1). According RECIST, best tumour response was partial response in 2 patients (40%) and disease progression in 3 (60%).

Two patients reported immune-related adverse events: grade 1 hyperthyroidism (Case 2) and grade 3 immunological thrombocytopenic purpura (Case 4). None of the patients experienced IRIS, not even Case 4, who received pembrolizumab concomitantly with HIV treatment by HAART.

HIV load remained or became (Case 4) undetectable at cut-off and blood CD4+ lymphocyte counts remained stable in all patients.

Discussion

Here we report 5 cases of PLWHIV with advanced NSCLC treated with first-line pembrolizumab immunotherapy. No severe or fatal toxicity, opportunistic infections, or IRIS were reported during follow-up. Our safety results are consistent with retrospective series reported in the systematic review by COOK et al. (13 articles plus 4 reports from meetings including various types of cancers in PLWHIV receiving ipilimumab, pembrolizumab, nivolumab, or atezolizumab) [4] and the observational study by SPANO et al. (2019) [9], which included 23 PLWHIV suffering from various malignancies (NSCLC [not including our cases], melanoma, head and neck cancers) and receiving pembrolizumab (first-, second- or subsequent lines) or nivolumab (≥second line). This study reported only 1 case of grade 3 immune-related interstitial lung disease after pembrolizumab.

We also assessed the effectiveness of ICI in these HIV-immunosuppressed patients and found an average survival of 9.8 months. Due to the small sample size, we cannot compare these data to larger studies in the general population [3]. Three patients had rapid progression occurring only after 1-5 treatment cycles, despite the high PD-L1 tumour expression (>50%). In contrast, of 2 patients with partial response, one (Case 2) had 2 additional cycles after data collection (9 in total), then progressed and started chemotherapy (overall survival of 24 months); and the other had a longer-term response (Case 4, 28 treatment cycles).

However, high PD-L1 expression is only one prognostic factor of response to anti-PD-L1 immunotherapy and other potential markers are unknown. For example, one of our non-responders (Case 3) had 80% tumour PD-L1 expression, but was also a non-smoker, a condition which is unrelated to tumour immune response – even with high PD-L1 expression.
[10] – but rather relates to the activation of molecular pathways of addiction. Even if no EGFR or ALK mutations were seen in this patient, many others were not assessed. Alternatively, immunotherapy may be combined with chemotherapy in these patients, with a potential synergistic effect and improved response. Besides addiction pathways, another factor to be considered in PLWHIV is HIV-induced immune cell qualitative abnormality, which could potentiate cancer cell-mediated immunosuppression via PD-L1.

As for anti-HIV response, despite high expectations of anti-PD-1/anti-PD-L1 immunotherapy that followed in vitro studies showing the reestablishment of anti-HIV immune response, recent in vivo observations did not support these results. Indeed, ICIs did not seem to modify viral parameters in stable PLWHIV or impact the response to HAART in newly discovered PLWHIV (Case 4) [4,9].

Finally, our results are consistent with previous observations by OSTIOS-GARCIA et al. (2018) on 3 PLWHIV with advanced NSCLC receiving first-line pembrolizumab [11]. Since this study, 3 more clinical trials [5,12,13] in PLWHIV have been published (Table 1). PLWHIV were also included in 2 additional phase III therapeutic trials, evaluating cemiplimab monotherapy as first-line treatment for advanced NSCLC with PD-L1 >50% [14] and nivolumab in combination with low-dose ipilimumab versus platinum doublet chemotherapy [15]. However, results for this group of patients have not been reported yet.

Indeed, we have to consider HIV patients with uncontrolled infections separately, because all previous studies included patients with controlled immune response at baseline. Prior antiretroviral therapy is recommended in HIV patients who have uncontrolled infections (as evidenced by high viral load and low CD4+ cell counts), since the effectiveness of immunotherapy in these patients is unknown.

**Conclusion**

We report 5 PLWHIV with NSCLC treated with first-line pembrolizumab immunotherapy. As well as safety and drug-to-drug interactions, the effectiveness of first-line immunotherapy in PLWHIV needs to be supported by large studies.

Inclusion of specific populations such as PLWHIV in clinical trials remains marginal, leading to considerable delays in drafting recommendations for these particularly at-risk patients.
Table 1. Outcome of immune checkpoint inhibitor therapy in PLWHIV with advanced stage cancers.

<table>
<thead>
<tr>
<th>Source</th>
<th>Case #</th>
<th>PS</th>
<th>Tumour type</th>
<th>Baseline CD4* cells/mm$^3$</th>
<th>Baseline VL (copies/mL)</th>
<th>Tumour PD-L1 (%)</th>
<th>ICI therapy (treatment line)</th>
<th>Best tumour response</th>
<th>CD4* cells/m$^3$ at cut-off$^2$</th>
<th>VL at cut-off$^2$ (copies/mL)</th>
<th>Survival (months)</th>
<th>Status at cut-off$^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>CANCERVIH</td>
<td>1</td>
<td>2</td>
<td>Adenocarcinoma</td>
<td>413</td>
<td>&lt;30</td>
<td>80</td>
<td>29 Aug 2018</td>
<td>Progression</td>
<td>319</td>
<td>&lt;30</td>
<td>9</td>
<td>Death (May 2019)</td>
</tr>
<tr>
<td>CANCERVIH</td>
<td>2</td>
<td>0</td>
<td>Undifferentiated carcinoma</td>
<td>1000</td>
<td>&lt;30</td>
<td>60</td>
<td>08 Aug 2019</td>
<td>Partial response</td>
<td>342</td>
<td>&lt;30</td>
<td>8</td>
<td>Alive (death in Sept 2020)</td>
</tr>
<tr>
<td>CANCERVIH</td>
<td>3</td>
<td>0</td>
<td>Squamous carcinoma</td>
<td>463</td>
<td>&lt;30</td>
<td>80</td>
<td>01 Apr 2019</td>
<td>Progression</td>
<td>N/A</td>
<td>&lt;30</td>
<td>3</td>
<td>Death (July 2019)</td>
</tr>
<tr>
<td>CANCERVIH</td>
<td>4</td>
<td>0</td>
<td>Squamous carcinoma</td>
<td>76</td>
<td>44500</td>
<td>≥50</td>
<td>13 Feb 2018</td>
<td>Partial response</td>
<td>N/A</td>
<td>&lt;30</td>
<td>25</td>
<td>Alive</td>
</tr>
<tr>
<td>CANCERVIH</td>
<td>5</td>
<td>1</td>
<td>Undifferentiated carcinoma</td>
<td>1024</td>
<td>&lt;30</td>
<td>≥50</td>
<td>23 Jan 2019</td>
<td>Progression</td>
<td>1230</td>
<td>&lt;30</td>
<td>4</td>
<td>Death (May 2019)</td>
</tr>
</tbody>
</table>

Source: N$^1$ | PS | Tumour type | Baseline CD4* cell count | Baseline VL (copies/mL) | Tumour PD-L1 (%) | ICI therapy (treatment line) | Best tumour response | CD4* cells/m$^3$ at cut-off$^2$ | VL at cut-off$^2$ (copies/mL) | Overall survival (months) | Adverse events |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CANCERVIH</td>
<td>1</td>
<td>2</td>
<td>Adenocarcinoma</td>
<td>413</td>
<td>&lt;30</td>
<td>80</td>
<td>29 Aug 2018</td>
<td>Progression</td>
<td>1230</td>
<td>&lt;30</td>
<td>4</td>
</tr>
<tr>
<td>CANCERVIH</td>
<td>2</td>
<td>0</td>
<td>Undifferentiated carcinoma</td>
<td>690</td>
<td>&lt;30</td>
<td>100</td>
<td>06 Aug 2018</td>
<td>Progression</td>
<td>1230</td>
<td>&lt;30</td>
<td>4</td>
</tr>
<tr>
<td>CANCERVIH</td>
<td>3</td>
<td>0</td>
<td>Squamous carcinoma</td>
<td>968</td>
<td>&lt;30</td>
<td>80</td>
<td>01 Apr 2019</td>
<td>Partial response</td>
<td>312</td>
<td>&lt;30</td>
<td>3</td>
</tr>
<tr>
<td>CANCERVIH</td>
<td>4</td>
<td>0</td>
<td>Squamous carcinoma</td>
<td>1230</td>
<td>&lt;30</td>
<td>100</td>
<td>01 Apr 2019</td>
<td>Partial response</td>
<td>312</td>
<td>&lt;30</td>
<td>3</td>
</tr>
<tr>
<td>CANCERVIH</td>
<td>5</td>
<td>1</td>
<td>Undifferentiated carcinoma</td>
<td>1230</td>
<td>&lt;30</td>
<td>100</td>
<td>01 Apr 2019</td>
<td>Partial response</td>
<td>312</td>
<td>&lt;30</td>
<td>3</td>
</tr>
</tbody>
</table>


*deteminated through investigator-assessed RECIST

$^1$ pembrolizumab start date.

$^2$ Cut-off date was March 2020.

$^3$ Number of included patients.
References:


